2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. SHP1

SHP1

Shp1; PTPN6; Src homology region 2 (SH-2) domain-containing phosphatase 1

SHP1 is a protein tyrosine phosphatase (PTP) that plays a crucial role in regulating various signaling pathways, particularly in hematopoietic cells and the immune system. This is particularly apparent in motheaten (me) mice that have a spontaneous mutation in Ptpn6, resulting in loss of SHP1, and develop a broad array of inflammatory and autoimmune symptoms.

SHP1 Related Products (22):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100463
    TPI-1
    		Inhibitor 98.0%
    TPI-1, also known as Tyrosine Phosphatase Inhibitor 1, is a SHP-1 inhibitor; inhibits recombinant SHP-1 with an IC50 of 40 nM.
    TPI-1
  • HY-136657
    SC-43
    		Inhibitor 99.01%
    SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects.
    SC-43
  • HY-18756
    NSC-87877
    		Inhibitor ≥99.0%
    NSC-87877 is a potent inhibitor of Shp2 and Shp1 protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC50 values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits dual-specificity phosphatase 26 (DUSP26).
    NSC-87877
  • HY-119024
    BCI-137
    		Inhibitor 99.84%
    BCI-137 is a Argonaute 2 (AGO2) inhibitor. By inhibiting AGO2 function, reducing PTPN6/SHP-1 protein levels and enhancing STAT1 phosphorylation, BCI-137 restores the sensitivity of tumor cells to IFN-γ. BCI-137 effectively enhances the recruitment, activation and cytotoxicity of CD8+ T cells. BCI-137 exerts a synergistic effect with anti-PD-1 antibodies and significantly reduces tumor volume in preclinical mouse models. BCI-137 exhibits favorable safety profiles and does not cause significant weight loss or death in mice. BCI-137 can be used in research related to bladder cancer, colorectal cancer, melanoma and other related fields.
    BCI-137
  • HY-112368
    PHPS1
    		Inhibitor 99.77%
    PHPS1 is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.
    PHPS1
  • HY-P992290
    Anti-PILRA Antibody
    Anti-PILRA Antibody is a monoclonal antibody that targets PILRA. Anti-PILRA Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PILRA Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-PILRA Antibody
  • HY-P992214
    Anti-CD84 Antibody
    Anti-CD84 Antibody is a monoclonal antibody that targets CD84. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD84 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD84 Antibody
  • HY-P992207
    Anti-CD300A Antibody
    Anti-CD300A Antibody is a monoclonal antibody targeting CD300A. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CD300A Antibody, please refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-CD300A Antibody
  • HY-168929
    SHP1 activator 1
    		Inhibitor 99.38%
    SHP1 activator 1 (Compound 3n) is an activator for src homology-2 domain-containing protein tyrosine phosphatase 1(SHP1) with an EC50 of 17.66 μM. SHP1 activator 1 inhibits the proliferation of ABC-DLBCL cells, induces apoptosis by inhibiting STAT3 signaling pathway. SHP1 activator 1 emitts blue and green fluorescence signalis in MDA-MB-231 cell, and can be used as a cell imaging agent.
    SHP1 activator 1
  • HY-N12614
    Diorcinol
    		Inhibitor 99.30%
    Diorcinol is a potent SHP1 inhibitor with an IC50 value of 0.96 μM. Diorcinol can be isolated from Aspergillus sydowii. Diorcinol has good blood-brain barrier penetration and can be used for diabetes research.
    Diorcinol
  • HY-18756A
    NSC-87877 disodium
    		Inhibitor 98.0%
    NSC-87877 disodium is a potent inhibitor of Shp2 and Shp1 protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC50 values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits dual-specificity phosphatase 26 (DUSP26).
    NSC-87877 disodium
  • HY-108944
    LYP-IN-1
    		Inhibitor 99.82%
    LYP-IN-1 is a potent, selective and specific LYP inhibitor with a Ki and an IC50 of 110 nM and 0.259 μM, respectively. LYP-IN-1 also has selectivity for a large panel of PTPs, such as SHP1 (IC50=5 μM) and SHP2 (IC50=2.5 μM). LYP-IN-1 exhibits highly efficacious cellular activity in T- and mast cells. LYP-IN-1 can be used for the study of autoimmune disorders. LYP-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LYP-IN-1
  • HY-125108
    PHPS1 sodium
    		Inhibitor 99.93%
    PHPS1 sodium is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.
    PHPS1 sodium
  • HY-N12613
    Sydowimide A
    		Inhibitor
    Sydowimide A is a potent inhibitor of Src homology region 2 domain-containing phosphatase-1 (SHP1), T-cell protein tyrosine phosphatase (TCPTP) and leukocyte common antigen (CD45), with IC50 values of 1.5, 2.4 and 18.83 μM, respectively.
    Sydowimide A
  • HY-152208
    BPDA2
    		Inhibitor 99.30%
    BPDA2 is a highly selective and competitive active site SHP2 inhibitor with IC50s of 92.0 nM, 33.39 μM, 40.71 μM for SHP2, SHP1, SHP1B, respectively. DBDA2 downregulates mitogenic and cell survival signaling and RTK expression. BPDA2 suppresses SHP2 mediated signaling and breast cancer cell phenotypes.
    BPDA2
  • HY-120901
    II-B08
    		Inhibitor
    II-B08 is a reversible and noncompetitive SHP2 inhibitor (IC50: 5.5 μM, 15.7, 14.3 μM for SHP2, SHP1, PTP1B). II-B08 can be used for cancer research.
    II-B08
  • HY-120159
    GS-493
    		Inhibitor
    GS-493 is a selective protein tyrosine phosphatase SHP2 (PTPN11) inhibitor with an IC50 of 71 nM. GS-493 is 29- and 45-fold more active toward SHP2 than related SHP1 and PTP1B. GS-493 blocks cellular motility and growth of cancer cells. Antitumor activity.
    GS-493
  • HY-W717425
    SC-60
    		Agonist
    SC-60 is a derivative of Sorafenib (HY-10201). SC-60 exerts its anti-tumor effect by activating the phosphatase activity of SHP-1, thereby inhibiting the STAT3 signaling pathway. SC-60 exhibits strong proliferation inhibitory activity in various hepatocellular carcinoma (HCC) cell lines. SC-60 downregulates the expression of downstream anti-apoptotic proteins (such as Bcl-2, Cyclin D1, Survivin), ultimately inducing caspase-dependent apoptosis. SC-60 significantly inhibits tumor growth in xenograft tumor models. SC-60 can be used for the study of HCC.
    SC-60
  • HY-N12177
    Cryptosporioptide A
    		Inhibitor
    Cryptosporioptide A (Compound 3) is a pigment protein tyrosine phosphatase inhibitor derived from the insect-parasitic fungus Cordyceps gracilioides. Cryptosporioptide A inhibits PTP1B, SHP2, CDC25B, LAR and SHP1 enzymes with IC50 of 7.3, 5.7, 7.6, >50, 4.9 μg/mL, respectively.
    Cryptosporioptide A
  • HY-D2204
    SHP1-IN-1
    		Inhibitor
    SHP1-IN-1 (compound 5p) is a fluorescent probe for the protein tyrosine phosphatase SHP1 containing the Src homology 2 domain. SHP1-IN-1 has SHP1 inhibitory activity, selectivity for Fe3+ ions and good fluorescence properties. SHP1-IN-1 exhibits aggregation post-quenching (ACQ) effect, good interference immunity and low detection limit (5.55 μM).
    SHP1-IN-1